30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Ambrx Biopharma Cayman Inc (AMAM)

Track

The most recent insider trading activity occurred in December 2023, with significant proposed sales by HOPU Reunion Co Ltd, an entity affiliated with a former director. Earlier in October 2023, the CFO and CEO also engaged in proposed sales. In contrast, Cormorant Asset Management, LP made several substantial purchases in October and September 2023, and also in April 2023.
Stock chart
Ticker: AMAM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
HOPU Reunion Co Ltd
Affiliated with former director
1 sale — total 19,772,502 USD
Proposed sale 26 Dec 2023
Value US$182,526.14 | Price 242.34 | Shares 55,814
Proposed sale 19 Dec 2023
Value US$4,281,325.61 | Price 267.23 | Shares 89,428
Proposed sale 8 Dec 2023
Value US$14,927,000.00 | Price 12.65 | Shares 1,180,000
Proposed sale 5 Dec 2023
Value US$12,020,000.00 | Price 12.02 | Shares 1,000,000
Proposed sale 1 Dec 2023
Value US$7,032,000.00 | Price 11.72 | Shares 600,000
Proposed sale 27 Oct 2023
Value US$491,167.85 | Price 9.82 | Shares 50,012
Planned sale 27 Oct 2023
Value US$491,117.84 | Price 9.82 | Shares 50,012
Planned sale 27 Oct 2023
Value US$125,479.96 | Price 9.82 | Shares 12,778
Proposed sale 27 Oct 2023
Value US$125,492.74 | Price 9.82 | Shares 12,778
Buy 23 Oct 2023
Value US$9,139,541.93 | Price 6.99 | Shares 1,307,311
Buy 18 Sep 2023
Value US$6,944,923.72 | Price 9.24 | Shares 751,233
Buy 15 Sep 2023
Value US$12,680,677.09 | Price 9.05 | Shares 1,401,505
Buy 20 Apr 2023
Value US$10,285,220.39 | Price 11.60 | Shares 886,634
Buy 19 Apr 2023
Value US$10,612,357.49 | Price 11.15 | Shares 951,909
Buy 18 Apr 2023
Value US$38,053,112.10 | Price 11.27 | Shares 3,376,646
Buy 17 Apr 2023
Value US$5,999,461.22 | Price 10.67 | Shares 562,121
Buy 14 Apr 2023
Value US$8,384,307.39 | Price 9.96 | Shares 841,967
Buy 13 Apr 2023
Value US$10,935,520.04 | Price 9.16 | Shares 1,193,808
Buy 16 Mar 2023
Value US$5,074,250.00 | Price 10.15 | Shares 500,000
Buy 15 Mar 2023
Value US$2,648,875.00 | Price 10.60 | Shares 250,000
Buy 14 Mar 2023
Value US$2,488,275.00 | Price 9.95 | Shares 250,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-12-26 2023-12-26 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
55,814
242.34
US$182,526 		55,814 242.34 US$182,526
2023-12-19 2023-12-19 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
89,428
267.23
US$4,281,326 		89,428 267.23 US$4,281,326
2023-12-08 2023-12-08 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
94,164
322.58
US$4,530,851 		94,164 322.58 US$4,530,851
2023-12-05 2023-12-05 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
1,000,000
12.02
US$12,020,000 		1,000,000 12.02 US$12,020,000
2023-12-01 2023-12-01 PrS Proposed sale
HOPU Reunion Co Ltd

Affiliated with former director

Non-Executive Director
600,000
11.72
US$7,032,000 		600,000 11.72 US$7,032,000
2023-11-01 2023-10-27 PrS Proposed sale
3.3
O'Connor Daniel J.

CEO
50,012
9.82
US$491,168 		50,012 9.82 US$491,168
2023-10-31 2023-10-27 PlS Planned sale
Nelson Sonja

Chief Financial Officer

Officer
12,778 -8.9%
9.82
US$125,480 		12,778 -8.9% 9.82 US$125,480
2023-10-31 2023-10-27 PlS Planned sale
3.3
O'Connor Daniel J.

President and CEO

Executive Director
50,012 -12.7%
9.82
US$491,118 		50,012 -12.7% 9.82 US$491,118
2023-10-27 2023-10-27 PrS Proposed sale
Nelson Sonja

CFO
12,778
9.82
US$125,493 		12,778 9.82 US$125,493
2023-10-25 2023-10-23 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
1,307,311 +13.2%
6.99
US$9,139,542 		1,307,311 +13.2% 6.99 US$9,139,542
2023-09-19 2023-09-18 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
751,233 +1.1%
9.24
US$6,944,924 		751,233 +1.1% 9.24 US$6,944,924
2023-09-19 2023-09-15 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
1,401,505 +2.1%
9.05
US$12,680,677 		1,401,505 +2.1% 9.05 US$12,680,677
2023-04-20 2023-04-20 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
886,634 +1.3%
11.60
US$10,285,220 		886,634 +1.3% 11.60 US$10,285,220
2023-04-20 2023-04-19 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
951,909 +1.5%
11.15
US$10,612,357 		951,909 +1.5% 11.15 US$10,612,357
2023-04-20 2023-04-18 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
3,376,646 +5.4%
11.27
US$38,053,112 		3,376,646 +5.4% 11.27 US$38,053,112
2023-04-17 2023-04-17 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
562,121 +0.9%
10.67
US$5,999,461 		562,121 +0.9% 10.67 US$5,999,461
2023-04-17 2023-04-14 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
841,967 +1.4%
9.96
US$8,384,307 		841,967 +1.4% 9.96 US$8,384,307
2023-04-17 2023-04-13 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
1,193,808 +2.0%
9.16
US$10,935,520 		1,193,808 +2.0% 9.16 US$10,935,520
2023-03-16 2023-03-16 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
500,000 +0.9%
10.15
US$5,074,250 		500,000 +0.9% 10.15 US$5,074,250
2023-03-16 2023-03-15 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
250,000 +0.5%
10.60
US$2,648,875 		250,000 +0.5% 10.60 US$2,648,875
2023-03-16 2023-03-14 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
250,000 +0.5%
9.95
US$2,488,275 		250,000 +0.5% 9.95 US$2,488,275
Explore more

More insider trading research around Ambrx Biopharma Cayman Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America